Patients with melanoma brain metastases that have BRAF V600E alterations have worse outcomes, according to a new analysis appearing in JAMA Network Open.
Clinical Trials
Fianlimab Combined With Cemiplimab Elicits Durable Responses in Advanced Melanoma
In an interview with Targeted Oncology, Omid Hamid, MD, discussed the efficacy of fianlimab in combination with cemiplimab for advanced melanoma. The results of the study show new possibilities for treating patients who have failed adjuvant anti PD-1 therapy.
Follow-Up Study Confirms Safety, Efficacy of Neoadjuvant Immunotherapy in Resectable Cutaneous Melanoma
Study with longer follow-up confirms outcomes of neoadjuvant plus adjuvant programmed cell death receptor 1 (PD-1) inhibition with resection in patients with resectable stage III/IV cutaneous melanoma, according to a study recently published in the Annals of Oncology.
Merck, Moderna Launch Pivotal Cancer Vaccine Trial for High-Risk Melanoma
Merck and Moderna announced Wednesday the initiation of a pivotal Phase III high-risk melanoma trial combining the companies’ mRNA-based personalized cancer vaccine with Merck’s blockbuster Keytruda checkpoint inhibitor.